BIOKIN
02615----
BIOKIN (02615)
Sichuan Biokin Pharmaceutical Co.,Ltd. engages in the research and development, production, and supply of biomedicine in the fields of antibody drug conjugate,...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- 0
- Turnover
- 0
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- 0.00
- Turnover Ratio
- --
News
- Unusual Whales · Jul 17 at 07:27 AM
SystImmune Announces Second Approval of Iza-bren in China for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
- Global Report · Jul 7 at 05:38 AM
Mobile’s Cash Flow Surges 128% as Gome Resorts to Share Issuance for Debt Survival
- prnewswire · Jun 22 at 02:09 PM
15:07 ETSystImmune Announces First Approval of Iza-bren for the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma in China
- biopharmadive · Feb 26 at 07:55 PM
Bristol Myers says ADC licensed from China hits mark in aggressive breast cancer
- Wallstreetcn · Dec 7, 2025 at 04:48 AM
Biokin Pharmaceutical T-Bren (HER2 ADC) demonstrates best-in-class potential, revealing efficacy data for treated HER2 mutated NSCLC for the first time, with a 12-month PFS rate of 73.5%
- etnet · Nov 6, 2025 at 05:59 PM
【New Stock Listing】BIOKIN (2615) subscription entry fee is 39,293 yuan, and 5 funds including the US-listed pharmaceutical company BMS are invested in the stock
